Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban in elective PCI
NCT01442792Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2011
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of rivaroxaban in coronary artery disease (CAD) (4 arms), sponsored by Bayer. Primary endpoints: Percentage of subjects requiring bail-out anticoagulant therapy, Percentage of subjects with angiographic flow limiting thrombotic event and 2 more. Started Oct 2011; status: completed.
02
Drugs
rivaroxaban
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01442792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01442792.